Efficacy projection of obiltoxaximab for treatment of inhalational anthrax across a range of disease severity

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5787-5795

  Yamamoto, Brent J ^a,e   Shadiack, Annette M ^a,f   Carpenter, Sarah ^a,g   Sanford, Daniel ^b   Henning, Lisa N ^b   O'Connor, Edward ^a,h   Gonzales, Nestor ^a,i   Mondick, John ^c   French, Jonathan ^c   Stark, Gregory V ^b   Fisher, Alan C ^d   Casey, Leslie S ^a   Serbina, Natalya V ^a  

^a Elusys Therapeutics Inc   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Metrum Research Group LLC   (United States)

^d BDM Consulting Inc   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f TherapeuticsMD   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

ⁱ VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX ANTIBODY; BACTERIAL ANTIGEN; OBILTOXAXIMAB; PLACEBO; ANTIINFECTIVE AGENT; ANTITOXIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN DETECTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL SPORE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FEVER; MACACA FASCICULARIS; MALE; MONKEY MODEL; MONOTHERAPY; NONHUMAN; ORYCTOLAGUS CUNICULUS; PRIORITY JOURNAL; RABBIT MODEL; SINGLE DRUG DOSE; SURVIVAL RATE; TOXEMIA; ANIMAL; MORTALITY; RABBITS AND HARES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTITOXINS; FEMALE; MACACA FASCICULARIS; MALE; RABBITS; RESPIRATORY TRACT INFECTIONS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84992360796     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00972-16     Document Type: Article

References (36)

1. Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D. 2015. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64:1-22. http://dx.doi.org/10.15585/mmwr.rr6404a1.
2. Adalja AA, Toner E, Inglesby TV. 2015. Clinical management of potential bioterrorism-related conditions. N Engl J Med 372:954-962. http://dx.doi.org/10.1056/NEJMra1409755.
3. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonnier NR, Rotz LD, Meyer RF, Stephens DS. 2007. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 44:968-971. http://dx.doi.org/10.1086/512372.
4. Anaraki S, Addiman S, Nixon G, Krahe D, Ghosh R, Brooks T, Lloyd G, Spencer R, Walsh A, McCloskey B, Lightfoot N. 2008. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill 13:19076.
5. Sykes A, Brooks T, Dusmet M, Nicholson AG, Hansell DM, Wilson R. 2013. Inhalational anthrax in a vaccinated soldier. Eur Respir J 42:285-287. http://dx.doi.org/10.1183/09031936.00201112.
6. Sprenkle MD, Griffith J, Marinelli W, Boyer AE, Quinn CP, Pesik NT, Hoffmaster A, Keenan J, Juni BA, Blaney DD. 2014. Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, U S A. Emerg Infect Dis 20:310-314. http://dx.doi.org/10.3201/eid2002.130245.
7. Griffith J, Blaney D, Shadomy S, Lehman M, Pesik N, Tostenson S, Delaney L, Tiller R, DeVries A, Gomez T, Sullivan M, Blackmore C, Stanek D, Lynfield R. 2014. Investigation of inhalation anthrax case, United States. Emerg Infect Dis 20:280-283. http://dx.doi.org/10.3201/eid2002.130021.
8. Guarner J, Jernigan JA, Shieh WJ, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR. 2003. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 163:701-709. http://dx.doi.org/10.1016/S0002-9440(10)63697-8.
9. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. 2006. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144:270-280. http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00009.
10. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8:1019-1028. http://dx.doi.org/10.3201/eid0810.020353.
11. Liu S, Moayeri M, Leppla SH. 2014. Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol 22:317-325. http://dx.doi.org/10.1016/j.tim.2014.02.012.
12. Guichard A, Nizet V, Bier E. 2012. New insights into the biological effects of anthrax toxins: linking cellular to organismal responses. Microbes Infect 14:97-118. http://dx.doi.org/10.1016/j.micinf.2011.08.016.
13. Moayeri M, Leppla SH, Vrentas C, Pomerantsev AP, Liu S. 2015. Anthrax pathogenesis. Annu Rev Microbiol 69:185-208. http://dx.doi.org/10.1146/annurev-micro-091014-104523.
14. Froude JW, II, Thullier P, Pelat T. 2011. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins 3:1433-1452. http://dx.doi.org/10.3390/toxins3111433.
15. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA. 2014. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 20:e130687.
16. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20:597-601. http://dx.doi.org/10.1038/nbt0602-597.
17. Rosovitz MJ. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278:30936-30944. http://dx.doi.org/10.1074/jbc.M301154200.
18. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73:795-802. http://dx.doi.org/10.1128/IAI.73.2.795-802.2005.
19. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135-144. http://dx.doi.org/10.1056/NEJMoa0810603.
20. Tsai CW, Morris S. 2015. Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration "Animal Rule." Front Microbiol 6:1320.
21. Gohil K. 2015. Pharmaceutical approval update. P T 40:362-363.
22. Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, Mott JM, Meister GT. 2012. Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. Clin Vaccine Immunol 19:1517-1525. http://dx.doi.org/10.1128/CVI.00292-12.
23. Henning LN, Comer JE, Stark GV, Ray BD, Tordoff KP, Knostman KA, Meister GT. 2012. Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaques. Clin Vaccine Immunol 19:1765-1775. http://dx.doi.org/10.1128/CVI.00288-12.
24. Vasconcelos D. 2003. Pathology of inhalation anthrax in Cynomolgus monkeys (Macaca fascicularis). Lab Investig 83:1201-1209. http://dx.doi.org/10.1097/01.LAB.0000080599.43791.01.
25. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982-992.
26. Yee SB, Hatkin JM, Dyer DN, Orr SA, Pitt ML. 2010. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Comp Med 60:461-468.
27. Kobiler D, Weiss S, Levy H, Fisher M, Mechaly A, Pass A, Altboum Z. 2006. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun 74:5871-5876. http://dx.doi.org/10.1128/IAI.00792-06.
28. Collier RJ, Young JA. 2003. Anthrax toxin. Annu Rev Cell Dev Biol 19:45-70. http://dx.doi.org/10.1146/annurev.cellbio.19.111301.140655.
29. U.S. FDA. 2001. Guidance for industry. Bioanalytical method validation. U.S. FDA, Washington, DC.
30. Lee JW, Hall M. 2009. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 877:1259-1271. http://dx.doi.org/10.1016/j.jchromb.2008.11.022.
31. Mehrotra DV, Chan IS, Berger RL. 2003. A cautionary note on exact unconditional inference for a difference between two independent binomial proportions. Biometrics 59:441-450. http://dx.doi.org/10.1111/1541-0420.00051.
32. Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, Rothschild N, Tal A, Schlomovitz J, Altboum Z. 2011. Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother 55:1533-1542. http://dx.doi.org/10.1128/AAC.01689-10.
33. Biron B, Beck K, Dyer D, Mattix M, Twenhafel N, Nalca A. 2015. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother 59:2206-2214. http://dx.doi.org/10.1128/AAC.04593-14.
34. Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, Chen C, Meister G. 2013. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits. Toxins (Basel) 5:120-138. http://dx.doi.org/10.3390/toxins5010120.
35. Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S. 2014. Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. PLoS One 9:e106393. http://dx.doi.org/10.1371/journal.pone.0106393.
36. Little SF, Leppla SH, Cora E. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56:1807-1813.